E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of hormone-refractory prostate cancer (HRPC) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10062904 |
E.1.2 | Term | Hormone-refractory prostate cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective is the comparison between the continuous therapy and the intermittent therapy. It should be shown that the intermittent therapy is not inferior to the continuous therapy with regard to the primary criterion, i.e. the 1-year survival rate. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are comparisons between both treatment arms concerning
- median survival-rate, median time-to-progression (TTP) and median time-to-failure (TTF). (The TTF is defined by the time until discontinuation of the treatment according to the study protocol. Within the intermittent arm, a progression occurring during the interval without therapy will not be included in the calculation of the TTP as an end point if the resumption of the treatment can prevent the occurrence of another progression "under treatment".)
- the proportion of the patients suffering from adverse events > grade 2 according to CTCAE 3.0 which have been caused by the therapy.
In addition, an exploratory comparison is planned between a weekly application and a three-weekly application with regard to all objectives of the trial. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• adenocarcinoma of the prostate confirmed by histology or cytology • metastasized adenocarcinoma of the prostate that is refractory to hormone treatment, ie, that does no longer respond to hormone therapy and/or the current treatment with estramustine • documented progression under the last therapy (definite PSA-increase that is confirmed by 2 subsequent measurements separated by at least 2 weeks, or increase of measurable lesions by at least 25% that is confirmed by radiological measurements) • previous hormone therapy • ECOG performance status <= 2 (Karnofsky index >= 60%) • adequate hematological, cardial and hepatic function defined by the following parameters: - absolute neutrophil count >= 2 x 109/l - thrombocytes >= 100 x 109/l - hemoglobin >=10 g/dl (6.2 mmol/l) - total serum bilirubin <= ULN - AST (SGOT) and ALT (SGPT) <= 1.5 x ULN - alkaline phosphatase <= 5 x ULN • life expectancy >= 12 weeks • written informed consent • age >= 18 years
|
|
E.4 | Principal exclusion criteria |
• previous therapy with isotopes • previous chemotherapy (except estramustine) • radiotherapy in the 4 weeks prior to enrollment • previous radiotherapy if this concerned all lesions that are used for the evaluation of tumor response • previous radiotherapy if this concerned more than 25% of bone marrow • previous or concomitant neoplasm (except curatively treated in situ carcinoma and basal cell carcinomas of the skin as well as curatively treated neoplasms without recurrence in the 5 years prior to enrollment • previous or current cerebral metastases or leptomeningeal involvement • current peripheral neuropathy >= grade 2 (CTCAE 3.0) • renal inusufficiancy requiring dialysis • chronic diarrhea (now or in medical history) • other relevant concomitant diseases: a) congestive heart failure or uncontrolled angina pectoris, previous myocardial infarction within 6 months prior to enrollment, uncontrolled arterial hypertension or arrhythmias b) known significant neurological or psychiatric diseases including dementia and epileptic seizures c) active infections requiring intravenous administration of antibiotics d) ulcerations, not stable diabetes mellitus or other contraindications with regard to the administration of high doses of corticosteroids e) untreated vena-cava-syndrome f) known ascites or pericardial effusion g) known symptomatic pleural effusion that requires tapping • concomitant treatment with other anti-tumor therapies except LHRH-agonists in a constant dose (for at least 4 weeks prior to enrollment) which should be continued • participation in a clinical trial within 30 days prior to enrollment • being anable to complie with therapy and investigations |
|
E.5 End points |
E.5.1 | Primary end point(s) |
-Progression of the disease under treatment -Occurrence of adverse events which are not allowing the continution of the treatment according to the study protocol. -The patient's request -Other reasons for which a continuation of the treatment according to the study protocol would not be in the patient's best intest. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
The continous therapy is compared to the intermittent therapy. |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 35 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial for each patient is defined by the final examination that will be performed 4 weeks after the last administration of Docetaxel. Within the scope of the optional follow-up, the date of the first progression (in case a progression date has not already been documented under therapy) and the date of death should be documented. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |